Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-7888 + Bevacizumab in Recurrent/Progressive Glioblastoma
NCT03149003Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2017
- Primary completion
- Aug 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of adegramotide + nelatimotide in glioblastoma (GBM), sponsored by Sumitomo Pharma America. Started Dec 2017; status: completed.
02
Drugs
adegramotide + nelatimotide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03149003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149003.